Caris Life Sciences, Inc.
CAI
$18.42
-$0.06-0.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 35.07% | 19.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 35.07% | 19.53% | |||
| Cost of Revenue | 1.12% | 2.38% | |||
| Gross Profit | 51.03% | 29.75% | |||
| SG&A Expenses | 12.13% | -12.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.01% | -7.62% | |||
| Operating Income | 170.85% | 281.46% | |||
| Income Before Tax | 236.92% | 133.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 236.92% | 133.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 236.92% | 133.88% | |||
| EBIT | 170.85% | 281.46% | |||
| EBITDA | 147.13% | 423.94% | |||
| EPS Basic | 236.89% | 101.08% | |||
| Normalized Basic EPS | 244.90% | 110.40% | |||
| EPS Diluted | 248.00% | 101.00% | |||
| Normalized Diluted EPS | 245.90% | 109.87% | |||
| Average Basic Shares Outstanding | 0.04% | 334.54% | |||
| Average Diluted Shares Outstanding | -0.38% | 357.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||